Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aceclofenac + paracetamol + chlorzoxazone is a fixed-dose combination (FDC) medication developed by Kriam Pharma for the symptomatic treatment of painful muscle spasms associated with musculoskeletal conditions. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting the cyclooxygenase-2 (COX-2) enzyme, thereby reducing the production of prostaglandins that cause pain and inflammation. Paracetamol acts as an additional analgesic and antipyretic, likely through the inhibition of prostaglandin synthesis in the central nervous system. Chlorzoxazone is a centrally acting skeletal muscle relaxant that inhibits multi-synaptic reflex arcs at the level of the spinal cord and subcortical areas of the brain, leading to muscle relaxation. This oral combination is typically used for conditions such as low back pain, sprains, and strains where both pain and muscle tension are present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aceclofenac + paracetamol + chlorzoxazone.